Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Ayalew Tefferi, MD, Kebede Begna, MD, Rebecca R. Laborde, PhD, Mrinal M Patnaik, MBBS, Terra L Lasho, MT, (ASCP), Darci Zblewski, Christy Finke, BS, Lauren Schimek, Betsy R. LaPlant, Curtis A. Hanson, MD, Monic J. Stuart, MD, MPH, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 662.

https://doi.org/10.1182/blood.V122.21.662.662

Published: 2013

Journal Articles

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Gabriela M. Baerlocher, MD, Elisabeth Oppliger Leibundgut, PharmD, Christina Ayran, Martha Blaney, PharmD, Bart Burington, Ph.D, Dianne Morfeld, Olatoyosi Odenike, MD, Oliver Ottman, MD, Anita Reddy, PhD, Alexander Roeth, MD, Gary Spitzer, MD, Monic J. Stuart, MD, MPH, Srdan Verstovsek, MD, PhD, David S. Snyder, MD

Blood (2012) 120 (21): 179.

https://doi.org/10.1182/blood.V120.21.179.179

Published: 2012

Journal Articles

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Carol Ann Huff, M.D., Quiju Wang, MS, Ashraf Z. Badros, MD, Richard J. Jones, Anita Reddy, PhD, Kevin Nishimoto, PhD, Monic J. Stuart, MD, MPH, Stephen M Kelsey, MD, William Matsui, MD

Blood (2012) 120 (21): 4898.

https://doi.org/10.1182/blood.V120.21.4898.4898

Published: 2012

Journal Articles

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,

Claudio Brunold, Thomas R Braschler, Ning Go, MD, Joi Ninomoto, PharmD, Hooman Kashani, MS DABT, Monic J. Stuart, MD, MPH, Elisabeth Oppliger Leibundgut, PharmD, Gabriela M. Baerlocher, MD

Blood (2011) 118 (21): 3843.

https://doi.org/10.1182/blood.V118.21.3843.3843

Published: 2011

Journal Articles

Effective Containment of Human Respiratory Syncytial Virus Infections in a Bone Marrow Transplantation Program Resulting from the Combined Implementation of Molecular Epidemiology, Infection Control, and Early Treatment Strategies.

Steven S. Cha, MD, Monic J. Stuart, MD, Susan Poutanen, MD, Sasha Madison, MD, Ellen Jo Baron, MD, Dean Erdman, MD, Janice M. Brown, MD.

Blood (2004) 104 (11): 2225.

https://doi.org/10.1182/blood.V104.11.2225.2225

Published: 2004

Journal Articles

Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8 + T-Cell Dose.

Thai M. Cao, MD, Judith A. Shizuru, PhD, MD, Ruby M. Wong, PhD, Kevin Sheehan, PhD, Ginna G. Laport, MD, Keith E. Stockerl-Goldstein, MD, Laura J. Johnston, MD, Monic J. Stuart, MD, Janic M.Y. Brown, MD, F. C. Grumet, MD, Robert S. Negrin, MD, Robert Lowsky, MD

Blood (2004) 104 (11): 183.

https://doi.org/10.1182/blood.V104.11.183.183

Published: 2004

NARROW

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,

Effective Containment of Human Respiratory Syncytial Virus Infections in a Bone Marrow Transplantation Program Resulting from the Combined Implementation of Molecular Epidemiology, Infection Control, and Early Treatment Strategies.

Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8 + T-Cell Dose.

Email alerts

ASH Publications

American Society of Hematology

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,

Effective Containment of Human Respiratory Syncytial Virus Infections in a Bone Marrow Transplantation Program Resulting from the Combined Implementation of Molecular Epidemiology, Infection Control, and Early Treatment Strategies.

Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8 + T-Cell Dose.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only